Feedback
Settings

Settings

Goto Application

247 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(MSGFOEBMIJOVCL-VPCXQMTMSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 25
1.WO/2025/250534T CELL TARGETS FOR TUBERCULOSIS VACCINES
WO - 04.12.2025
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
 Appl.No PCT/US2025/031027 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor DAVIS, Mark M.
The Mtb protein Rv2140c, specific peptide epitopes derived, and polynucleotide sequences encoding such polypeptides are disclosed herein as a useful TB antigen for generating a protective immune response to development of tuberculosis. In some embodiments the Rv2140c polypeptide or polynucleotide is formulated as a vaccine. In some embodiments the Rv2140c vaccine is administered to a naïve recipient. In some embodiments the Rv2140c vaccine is administered as a booster to a previously vaccinated to exposed individual. In some embodiments the previous vaccination is a BCG vaccination.
2.2025166811ＲＳＶ－ＦをコードするＲＮＡ分子およびそれを含有するワクチン
JP - 06.11.2025
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No 2025070092 Applicant ファイザー・インク Inventor ウェイ　チェン
【課題】肺炎および気管支炎を含む、ＲＳＶ感染誘導性の急性の気道の病気の処置および／または予防のための組成物を提供する。
【解決手段】ＲＳＶに対する免疫応答を誘導するための組成物であって、呼吸器合胞体ウイルス（ＲＳＶ）融合タンパク質Ｆ（Ｆ）ポリペプチドをコードする少なくとも１つのオープンリーディングフレームを含むＲＮＡ分子を含む組成物が提供される。本開示は、脂質ナノ粒子中に製剤化されたＲＮＡ分子（ＲＮＡ－ＬＮＰ）を含む組成物にさらに関する。本開示は、肺炎および気管支炎を含む、ＲＳＶ感染誘導性の急性の気道の病気の処置および／または予防のための、ＲＮＡ分子、ＲＮＡ－ＬＮＰ、および組成物の使用にさらに関する。
【選択図】なし
3.WO/2025/217126POLYNUCLEOTIDES, 3' CHAIN TERMINATING TAILS, LIGATION AND USES THEREOF
WO - 16.10.2025
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No PCT/US2025/023599 Applicant CONVERGENCE BIO, INC. Inventor WANG, Chong
The present disclosure provides constructs and methods for RNA ligation of 3' chain terminating tails and uses for improving nucleic acid stability and protein expression.
4.20250319160USE OF IFN-LAMBDA MRNA FOR TREATING VIRAL INFECTIONS
US - 16.10.2025
Int.Class A61K 38/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons
 Appl.No 19248327 Applicant ethris GmbH Inventor Carsten Rudolph

The present invention relates to pharmaceutical compositions comprising an mRNA encoding an IFN-λ polypeptide for use in treating a viral-induced disorder, preferably a viral-induced respiratory disorder, such as COVID-19.

5.WO/2025/217135RNA LIGATION METHODS AND PRODUCTS
WO - 16.10.2025
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No PCT/US2025/023609 Applicant CONVERGENCE BIO, INC. Inventor WANG, Chong
The present disclosure provides products of and methods comprising RNA ligation. In some embodiments, the method comprises contacting an RNA ligase enzyme with (i) an acceptor RNA polynucleotide comprising a 3' hydroxyl group and (ii) a donor RNA polynucleotide.
6.2025529925安定な脂質またはリピドイドナノ粒子懸濁液
JP - 09.09.2025
Int.Class A61K 47/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
 Appl.No 2025512010 Applicant エスリス　ゲーエムベーハー Inventor ドーメン，クリスチャン
安定化されている脂質ナノ粒子（ＬＮＰ）／リピドイドナノ粒子（ＬｉＮＰ）製剤およびＬＮＰ／ＬｉＮＰ懸濁液、それらの使用、ならびにサーファクタントを製剤または懸濁液に添加すると凝集が回避され、驚くほど長い貯蔵寿命および振とうに対する長期的な安定性が可能になるという知見に基づく処置の方法における使用が提供される。本発明による凝集の前記低減は、本発明の製剤および懸濁液の副作用の低減、具体的には、ＬＮＰおよび／またはＬｉＮＰを含むワクチン製剤および抗がん製剤によって引き起こされる副作用の低減をもたらす。
7.120285155IFN-λmRNA治疗病毒感染的用途
CN - 11.07.2025
Int.Class A61K 38/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons
 Appl.No 202510472800.1 Applicant 埃泽瑞斯公司 Inventor C·鲁道夫
本发明的名称是IFN‑λmRNA治疗病毒感染的用途。本发明涉及包括编码IFN‑λ多肽的mRNA的药物组合物，用于治疗病毒诱导的疾病，优选是病毒诱导的呼吸系统疾病，如COVID‑19。
8.20250215043RNA CAP ANALOGS AND METHODS OF USE
US - 03.07.2025
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No 18867199 Applicant NUTCRACKER THERAPEUTICS, INC. Inventor Colin James McKinlay

Provided herein are compounds that are cap analogs for polynucleotides, e.g., RNA molecules, such as mRNA molecules. Also provided are capped polynucleotides, e.g., capped RNA molecules, such as capped miRNA molecules, wherein the 5′ end of the RNA molecule comprises a cap analog disclosed herein, drug products comprising the capped RNA molecules, methods for making capped polynucleotides disclosed herein, and kits for making the capped polynucleotides.

9.1020250096808RSV-F를 인코딩하는 RNA 분자 및 이를 포함하는 백신
KR - 27.06.2025
Int.Class C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
 Appl.No 1020257017392 Applicant 화이자 인코포레이티드 Inventor 천 웨이
본 발명은 호흡기 세포융합 바이러스(RSV)를 인코딩하는 RNA 분자에 관한 것이다. 또한, 본 발명은 지질 나노입자(RNA-LNP)로 제형화된 RNA 분자를 포함하는 조성물에 관한 것이다. 또한, 본 발명은 폐렴 및 기관지염을 비롯한 RSV 감염-유발 급성 호흡기 질환의 치료 및/또는 예방을 위한 RNA 분자, RNA-LNP 및 조성물의 용도에 관한 것이다.
10.20250207163METHODS AND APPARATUS FOR SYNTHESIZING NUCLEIC ACIDS
US - 26.06.2025
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No 18850185 Applicant Molecular Assemblies, Inc. Inventor Patrycja A. Hopkins

Methods for the synthesis of polynucleotides using polymerases nucleotide analogs with labile terminator groups that allow stepwise addition of nucleotides are described. These nucleotide analogs may have a modification on 3′, 2′, or 3′-2′-bridged hydroxyl groups or on nucleobase moieties and can be used in the synthesis of natural or modified polynucleotides suitable for use in biological systems. The labile terminator groups are removed under mild conditions or by enzymes. They are accepted as substrates by polymerases. The synthesis may be carried out on a surface.

# -